Home2VSA • FRA
add
Verastem Inc
Previous close
€5.70
Day range
€5.55 - €5.70
Year range
€1.90 - €12.50
Market cap
276.83M USD
Avg Volume
131.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 37.03M | 73.78% |
Net income | -23.97M | -19.81% |
Net profit margin | — | — |
Earnings per share | -0.88 | -23.94% |
EBITDA | -37.02M | -73.78% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 113.18M | -31.68% |
Total assets | 126.38M | -28.26% |
Total liabilities | 94.16M | 31.12% |
Total equity | 32.22M | — |
Shares outstanding | 44.51M | — |
Price to book | 21.11 | — |
Return on assets | -79.76% | — |
Return on capital | -119.05% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -23.97M | -19.81% |
Cash from operations | -23.80M | -43.44% |
Cash from investing | 0.00 | 100.00% |
Cash from financing | 53.60M | 6,115.60% |
Net change in cash | 29.80M | 134.04% |
Free cash flow | -10.41M | 5.62% |
About
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia
Founded
2010
Headquarters
Website
Employees
73
